Aardvark Therapeutics, Inc. Common Stock

AARDNASDAQ • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
4.79 USD
↘ 0.27 (5.34%)AT CLOSE (11:59 AM EDT)
4.80
↗ 0.01 (0.10%)
POST MARKET (AS OF 04:32 PM EDT)
Post Market
AS OF 04:32 PM EDT
4.80
↗ 0.01 (0.10%)
🔴Market: CLOSED

Aardvark Therapeutics, Inc. Common Stock (AARD) trades at $4.79 per share. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Notable factors include a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 26, 2026.

Open?$5.15
High?$5.53
Low?$4.63
Prev. Close?$5.06
Volume?1.7M
Avg. Volume?225.5K
VWAP?$5.10
Rel. Volume?7.38x
Bid / Ask
Bid?$4.02 × 1.0K
Ask?$4.81 × 200
Spread?$0.79
Midpoint?$4.41
Valuation & Ratios
Market Cap?104.5M
Shares Out?21.8M
Float?12.2M
Float %?56.0%
P/E Ratio?N/A
P/B Ratio?1.20
EPS?-$3.20
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Themes
Biotech - Drug Development›Metabolic & CardiometabolicBiotech - Drug Development›Rare Disease Therapeutics
Employees
40
Market Cap
110.4M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.aardvarktherapeutics.com
Listed
2025-02-13
Address
4370 LA JOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122
Phone: (858) 225-7696
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
34
Momentum?
23
Short Sent.?
59
Piotroski F-Score?0/9Weak
Altman Z-Score?1.95Grey
Confidence?45%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?7.46%Elevated
Short Interest?911.8K
Days to Cover?7.0
Free Float12.2M
Avg Daily Volume131.0K
Settlement Date2026-06-15
Financial Health
Current Ratio?8.06Strong
Quick Ratio?8.06Strong
Cash Ratio?5.38Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
93
1.20CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-80.3%WEAK▾
ROA?
S&P
3
-70.9%WEAK▾
Cash Flow & Enterprise
FCF?$-61748000
Enterprise Value?$42.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist